反应详情

Using a similar procedure as described in Example #162, Step F-G, (R)-1-methyl-10-((R)-3-methyl-pyrrolidin-3-yl)-3,5-dihydro-10H-6-oxa-3,4,10,11b-tetraaza-cyclopenta[b]phenanthren-2-one (SFC (Table 1, Method 52) Rt=4.593 min 0.015 g, 5%) was prepared from (R)-3-((R)-7-bromo-4-methyl-3-oxo-2,3,4,10-tetrahydro-9-oxa-1,2,4a-triaza-phenanthren-6-ylamino)-3-methyl-pyrrolidine-1-carboxylic acid tert-butyl ester (isomer C, SFC (Table 1, Method 54), Rt=1.752 min, 0.45 g, 0.9 mmol). 1H NMR (400 MHz, DMSO-d6) δ 10.71 (brs, 1H), 7.34 (s, 1H), 7.29 (s, 1H), 7.16 (s, 1H), 6.31 (s, 1H), 5.09 (q, J=6.4 Hz, 1H), 4.54 (d, J=14.8 Hz, 2H), 3.11 (m, 4H), 2.45 (m, 2H), 1.57 (s, 3H), 1.32 (d, J=6.4 Hz, 3H). LC/MS (Table 1, Method 4) Rt=1.363 min; MS (ESI): m/z 340 [M+1]+.